Research ArticleHuman Immunology

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo

See allHide authors and affiliations

Science Translational Medicine  22 Apr 2015:
Vol. 7, Issue 284, pp. 284ra56
DOI: 10.1126/scitranslmed.aaa1983

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Immunotherapy according to GARP

Regulatory T cells (Tregs) play a critical role in preventing autoimmunity but can be co-opted by cancer cells to block immune surveillance of tumors. Cuende et al. report that a membrane protein, GARP, which binds transforming growth factor–β1 (TGF-β1) on the cell surface of Tregs, is involved in Treg-mediated inhibition of immune responses. What’s more, the authors develop anti-GARP monoclonal antibodies that block TGF-β1 production by Tregs and inhibit the activity of these cells in a xenogeneic mouse model of graft-versus-host disease. Thus, blocking GARP, either alone or in combination with other checkpoint inhibitors, could add to our arsenal for cancer immunotherapy.

View Full Text

Stay Connected to Science Translational Medicine